AstraZeneca PLC ADR (AZN) is a leading drug manufacturers - general business based in the US. It opened the day at $75.59 after a previous close of $74.93. During the day the price has varied from a low of $74.68 to a high of $75.90. The latest price was $74.93 (25 minute delay). AstraZeneca PLC ADR is listed on the NASDAQ and employs 94,300 staff. All prices are listed in US Dollars.
Offer ends 4/1/25. Customer must fund their Active invest account with at least $50 within 30 days of opening the account. Probability of customer receiving $2,000 is 0.028%. See full terms and conditions at https://www.sofi.com/greenintwoterms/.
Open an account.Provide your personal information and sign up.
Fund your account.Deposit funds into your account by linking your banking information or transfer funds from another trading account.
Search for the stock name – AZN.Search for the stock by name or ticker symbol.
Buy the stock. Place your order. It's that simple.
Buy AstraZeneca PLC ADR stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
AstraZeneca PLC ADR stock price (NASDAQ: AZN)
Use our graph to track the performance of AZN stocks over time.
Is it a good time to buy AstraZeneca PLC ADR stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
AstraZeneca PLC ADR price performance over time
Historical closes compared with the close of $74.93 from 2025-03-21
1 week (2025-03-14)
-3.44%
1 month (2025-02-24)
0.32%
3 months (2024-12-24)
13.02%
6 months (2024-09-24)
-2.52%
1 year (2024-03-22)
13.08%
2 years (2023-03-23)
16.16%
3 years (2022-03-23)
24.11%
5 years (2020-03-23)
116.72%
Is AstraZeneca PLC ADR stock undervalued or overvalued?
Valuing AstraZeneca PLC ADR stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AstraZeneca PLC ADR's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
AstraZeneca PLC ADR's P/E ratio
AstraZeneca PLC ADR's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 34x. In other words, AstraZeneca PLC ADR shares trade at around 34x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
AstraZeneca PLC ADR's PEG ratio
AstraZeneca PLC ADR's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.0876. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into AstraZeneca PLC ADR's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
AstraZeneca PLC ADR's EBITDA
AstraZeneca PLC ADR's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $17.6 billion.
The EBITDA is a measure of a AstraZeneca PLC ADR's overall financial performance and is widely used to measure a its profitability.
AstraZeneca PLC ADR financials
Revenue TTM
$54.1 billion
Operating margin TTM
22.72%
Gross profit TTM
$44.4 billion
Return on assets TTM
7.88%
Return on equity TTM
17.59%
Profit margin
13.01%
Book value
$26.30
Market Capitalization
$237.5 billion
TTM: trailing 12 months
AstraZeneca PLC ADR share dividends
Dividend payout ratio: 43.44% of net profits
Recently AstraZeneca PLC ADR has paid out, on average, around 0% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), AstraZeneca PLC ADR shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In AstraZeneca PLC ADR's case, that would currently equate to about $3.1 per share.
While AstraZeneca PLC ADR's payout ratio might seem fairly standard, it's worth remembering that AstraZeneca PLC ADR may be investing much of the rest of its net profits in future growth.
AstraZeneca PLC ADR's most recent dividend payout was on 23 March 2025. The latest dividend was paid out to all shareholders who bought their shares by 20 February 2025 (the "ex-dividend date").
Have AstraZeneca PLC ADR's shares ever split?
AstraZeneca PLC ADR's shares were
split on a 2:1 basis on 26 July 2015
. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your AstraZeneca PLC ADR shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for AstraZeneca PLC ADR shares which in turn could have impacted AstraZeneca PLC ADR's share price.
AstraZeneca PLC ADR share price volatility
Over the last 12 months, AstraZeneca PLC ADR's shares have ranged in value from as little as $61.8831 up to $86.4638. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AstraZeneca PLC ADR's is 0.157. This would suggest that AstraZeneca PLC ADR's shares are less volatile than average (for this exchange).
AstraZeneca PLC ADR overview
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Frequently asked questions
What percentage of AstraZeneca PLC ADR is owned by insiders or institutions? Currently 0.005% of AstraZeneca PLC ADR shares are held by insiders and 17.52% by institutions.How many people work for AstraZeneca PLC ADR? Latest data suggests 94,300 work at AstraZeneca PLC ADR.When does the fiscal year end for AstraZeneca PLC ADR? AstraZeneca PLC ADR's fiscal year ends in December.Where is AstraZeneca PLC ADR based? AstraZeneca PLC ADR's address is: 1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AAWhat is AstraZeneca PLC ADR's ISIN number? AstraZeneca PLC ADR's international securities identification number is: US0463531089What is AstraZeneca PLC ADR's CUSIP number? AstraZeneca PLC ADR's Committee on Uniform Securities Identification Procedures number is: 046353108
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.
Advertiser disclosure
Finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which Finder receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. Finder compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
How likely would you be to recommend Finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
